HUDSON, N.Y., April 03, 2017 -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, has launched ExpressMODEL™, an innovative and streamlined model generation service that reduces the timeline to first generation and experimental cohort by up to four months.
This novel model generation method significantly reduces the time required to create an experimental rodent cohort, enabling critical drug discovery testing to happen much faster, saving both time and money.
ExpressMODEL™ leverages Taconic’s extensive in vitro fertilization (IVF) expertise, optimizing procedures by using chimaeras to rapidly expand founder mice. This increases the number of mice carrying targeted alleles in the first generation from 3-4 to at least 20-30. By providing a sizeable colony of first generation heterozygous animals, ExpressMODEL™ allows researchers to skip at least one round of colony expansion, saving 3-4 months on the overall project timeline. Elimination of natural breeding in the germline transmission step results in predictable timelines and better experiment planning.
Unlike other methods employed to reduce timelines, ExpressMODEL™ does not rush critical genome modification procedures. The new Taconic approach preserves the use of stringent controls during the genome modification process, thereby minimizing the risk of generating a mouse model carrying the wrong transgenic allele or additional unwanted mutations.
“In drug discovery it is rare to find an innovation that saves time while increasing quality, as typically one is pursued at the expense of the other. ExpressMODEL™ represents a tremendous value for our customers because it can save up to four months of time, while creating more predictable timelines and consistent high quality,” shared John Couse, PhD, Portfolio Director for Taconic Scientific Services.
“Our model generation work is not done when we have a founder or breeding pair. With ExpressMODEL™, we provide our clients with research-ready cohorts so they can start their work immediately,” said Couse.
Taconic is a fully-licensed provider of rodent model generation services and has twenty years of model design experience, providing gene inactivation, gene mutation or replacement, transgene expression, RNAi, and gene editing via CRISPR/Cas9 technologies to ensure that the right tools are leveraged for each specific customer project. Complimenting this expertise is Taconic’s unique capability of providing a seamless transition from model design to breeding and colony management, thus offering customers a complete solution. These scientific services include acquiring or generating, importing, licensing, breeding, testing, preparing, and distributing genetically engineered models to any location worldwide.
To learn more about Taconic's custom model generation, please call 1-888-TACONIC (888-822-6642) in the US, or +45 70 23 04 05 in Europe, or email [email protected].
About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.
Media Contact: Kelly Owen Grover Director of Marketing Communications (518) 697-3824 [email protected]


Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 



